<<My guess is that any outcome short of an unconditional recommendation for approval puts the stock near or below its $21 IPO price. JMHO>>
Anything unfavorable I think $21 is a generous guess.
Pilot 1 program and the fda has clearly put the drug on a very expedited fast track. I think the chances for approval are better than not and am considering closing out my short <8/27.
Agree with your post approval assessment. Still questionable whether sales will support the rich market cap.
P.S. hopefully r-provigil will work better for you.
Market Data 
Markets 
AI
